Vounatsos Michel 4

4 · BIOGEN INC. · Filed Feb 15, 2022

Form 4

Period: 2022-02-12

EVP & Chief Commercial Officer

Transactions

Exercise/Conversion
Common Stock
2022-02-12+4,395→ 70,465.188 total
Exercise/Conversion
Restricted Stock Unit
2022-02-12−4,395→ 20,727 total
Exercise: $0.00Exp: 2023-02-12→ Common Stock (4,395 underlying)
Exercise/Conversion
Common Stock
2022-02-12+4,321→ 67,987.188 total
Tax Payment
Common Stock
2022-02-12$214.59/sh−1,950$418,451→ 68,515.188 total
Tax Payment
Common Stock
2022-02-12$214.59/sh−4,699$1,008,358→ 63,816.188 total
Other
Restricted Stock Unit
2022-02-12−8,205→ 0 total
Exercise: $0.00Exp: 2022-02-12→ Common Stock (8,205 underlying)
Tax Payment
Common Stock
2022-02-12$214.59/sh−1,917$411,369→ 66,070.188 total
Exercise/Conversion
Restricted Stock Unit
2022-02-12−4,321→ 8,205 total
Exercise: $0.00Exp: 2022-02-12→ Common Stock (4,321 underlying)
Other
Restricted Stock Unit
2022-02-12−8,163→ 12,564 total
Exercise: $0.00Exp: 2023-02-12→ Common Stock (8,163 underlying)

Footnotes (3)

[F1]Represents shares withheld to satisfy the withholding tax liability due upon vesting of shares, as previously disclosed by reporting person on January 21, 2022.
[F2]The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).
[F3]This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

Documents

1 file